137 related articles for article (PubMed ID: 24441743)
1. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Hassler MR; Ackerl M; Flechl B; Sax C; Wöhrer A; Widhalm G; Dieckmann K; Hainfellner J; Preusser M; Marosi C
Anticancer Drugs; 2014 Jul; 25(6):723-8. PubMed ID: 24441743
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Brämswig K; Ploner F; Martel A; Bauernhofer T; Hilbe W; Kühr T; Leitgeb C; Mlineritsch B; Petzer A; Seebacher V; Stöger H; Girschikofsky M; Hochreiner G; Ressler S; Romeder F; Wöll E; Brodowicz T
Anticancer Drugs; 2014 Aug; 25(7):848-53. PubMed ID: 24667659
[TBL] [Abstract][Full Text] [Related]
3. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
6. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
9. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
[TBL] [Abstract][Full Text] [Related]
12. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
13. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
18. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]